These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 31320402)

  • 1. Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify
    Talwelkar SS; Nagaraj AS; Devlin JR; Hemmes A; Potdar S; Kiss EA; Saharinen P; Salmenkivi K; Mäyränpää MI; Wennerberg K; Verschuren EW
    Mol Cancer Ther; 2019 Oct; 18(10):1863-1874. PubMed ID: 31320402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors.
    Bhatt V; Lan T; Wang W; Kong J; Lopes EC; Wang J; Khayati K; Raju A; Rangel M; Lopez E; Hu ZS; Luo X; Su X; Malhotra J; Hu W; Pine SR; White E; Guo JY
    Cell Death Dis; 2023 Jan; 14(1):61. PubMed ID: 36702816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The ERBB network facilitates KRAS-driven lung tumorigenesis.
    Kruspig B; Monteverde T; Neidler S; Hock A; Kerr E; Nixon C; Clark W; Hedley A; Laing S; Coffelt SB; Le Quesne J; Dick C; Vousden KH; Martins CP; Murphy DJ
    Sci Transl Med; 2018 Jun; 10(446):. PubMed ID: 29925636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in LKB1 Mutant, KRAS Driven NSCLC.
    Zhang H; Nabel CS; Li D; O'Connor RÍ; Crosby CR; Chang SM; Hao Y; Stanley R; Sahu S; Levin DS; Chen T; Tang S; Huang HY; Meynardie M; Stephens J; Sherman F; Chafitz A; Costelloe N; Rodrigues DA; Fogarty H; Kiernan MG; Cronin F; Papadopoulos E; Ploszaj M; Weerasekara V; Deng J; Kiely P; Bardeesy N; Vander Heiden MG; Chonghaile TN; Dowling CM; Wong KK
    J Thorac Oncol; 2023 Jul; 18(7):882-895. PubMed ID: 36958689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
    Molina-Arcas M; Moore C; Rana S; van Maldegem F; Mugarza E; Romero-Clavijo P; Herbert E; Horswell S; Li LS; Janes MR; Hancock DC; Downward J
    Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvianolic acid F suppresses KRAS-dependent lung cancer cell growth through the PI3K/AKT signaling pathway.
    Hou X; Zhou C; Liang Z; Qiu H; Zhou Z; Zheng H; Li Z; Wang Y; Qi X; Lu L; Cao Y; Zheng J
    Phytomedicine; 2023 Dec; 121():155093. PubMed ID: 37783131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combinatorial strategy for treating KRAS-mutant lung cancer.
    Manchado E; Weissmueller S; Morris JP; Chen CC; Wullenkord R; Lujambio A; de Stanchina E; Poirier JT; Gainor JF; Corcoran RB; Engelman JA; Rudin CM; Rosen N; Lowe SW
    Nature; 2016 Jun; 534(7609):647-51. PubMed ID: 27338794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.
    Molina-Arcas M; Hancock DC; Sheridan C; Kumar MS; Downward J
    Cancer Discov; 2013 May; 3(5):548-63. PubMed ID: 23454899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer.
    Ricciuti B; Son J; Okoro JJ; Mira A; Patrucco E; Eum Y; Wang X; Paranal R; Wang H; Lin M; Haikala HM; Li J; Xu Y; Alessi JV; Chhoeu C; Redig AJ; Köhler J; Dholakia KH; Chen Y; Richard E; Nokin MJ; Santamaria D; Gokhale PC; Awad MM; Jänne PA; Ambrogio C
    Clin Cancer Res; 2022 Apr; 28(8):1640-1650. PubMed ID: 35091439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.
    Momcilovic M; McMickle R; Abt E; Seki A; Simko SA; Magyar C; Stout DB; Fishbein MC; Walser TC; Dubinett SM; Shackelford DB
    Cancer Res; 2015 Nov; 75(22):4910-22. PubMed ID: 26574479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AXL targeting restores PD-1 blockade sensitivity of
    Li H; Liu Z; Liu L; Zhang H; Han C; Girard L; Park H; Zhang A; Dong C; Ye J; Rayford A; Peyton M; Li X; Avila K; Cao X; Hu S; Alam MM; Akbay EA; Solis LM; Behrens C; Hernandez-Ruiz S; Lu W; Wistuba I; Heymach JV; Chisamore M; Micklem D; Gabra H; Gausdal G; Lorens JB; Li B; Fu YX; Minna JD; Brekken RA
    Cell Rep Med; 2022 Mar; 3(3):100554. PubMed ID: 35492873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling.
    Morel M; Long W
    Mol Oncol; 2024 Mar; 18(3):762-777. PubMed ID: 37983945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy.
    Ndembe G; Intini I; Moro M; Grasselli C; Panfili A; Panini N; Bleve A; Occhipinti M; Borzi C; Garassino MC; Marabese M; Canesi S; Scanziani E; Sozzi G; Broggini M; Ganzinelli M
    J Exp Clin Cancer Res; 2024 Jan; 43(1):6. PubMed ID: 38163906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer.
    Ponz-Sarvise M; Corbo V; Tiriac H; Engle DD; Frese KK; Oni TE; Hwang CI; Öhlund D; Chio IIC; Baker LA; Filippini D; Wright K; Bapiro TE; Huang P; Smith P; Yu KH; Jodrell DI; Park Y; Tuveson DA
    Clin Cancer Res; 2019 Nov; 25(22):6742-6755. PubMed ID: 31492749
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
    Skoulidis F; Byers LA; Diao L; Papadimitrakopoulou VA; Tong P; Izzo J; Behrens C; Kadara H; Parra ER; Canales JR; Zhang J; Giri U; Gudikote J; Cortez MA; Yang C; Fan Y; Peyton M; Girard L; Coombes KR; Toniatti C; Heffernan TP; Choi M; Frampton GM; Miller V; Weinstein JN; Herbst RS; Wong KK; Zhang J; Sharma P; Mills GB; Hong WK; Minna JD; Allison JP; Futreal A; Wang J; Wistuba II; Heymach JV
    Cancer Discov; 2015 Aug; 5(8):860-77. PubMed ID: 26069186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers.
    Guerra SL; Maertens O; Kuzmickas R; De Raedt T; Adeyemi RO; Guild CJ; Guillemette S; Redig AJ; Chambers ES; Xu M; Tiv H; Santagata S; Jänne PA; Elledge SJ; Cichowski K
    Cancer Cell; 2020 May; 37(5):705-719.e6. PubMed ID: 32243838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucose-6-phosphate dehydrogenase maintains redox homeostasis and biosynthesis in LKB1-deficient KRAS-driven lung cancer.
    Lan T; Arastu S; Lam J; Kim H; Wang W; Wang S; Bhatt V; Lopes EC; Hu Z; Sun M; Luo X; Ghergurovich JM; Su X; Rabinowitz JD; White E; Guo JY
    Nat Commun; 2024 Jul; 15(1):5857. PubMed ID: 38997257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition.
    Xue JY; Zhao Y; Aronowitz J; Mai TT; Vides A; Qeriqi B; Kim D; Li C; de Stanchina E; Mazutis L; Risso D; Lito P
    Nature; 2020 Jan; 577(7790):421-425. PubMed ID: 31915379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in
    Stewart A; Coker EA; Pölsterl S; Georgiou A; Minchom AR; Carreira S; Cunningham D; O'Brien ME; Raynaud FI; de Bono JS; Al-Lazikani B; Banerji U
    Mol Cancer Ther; 2019 Aug; 18(8):1396-1404. PubMed ID: 31262731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of the Interaction of RAS with PI 3-Kinase Induces Regression of EGFR-Mutant-Driven Lung Cancer.
    Murillo MM; Rana S; Spencer-Dene B; Nye E; Stamp G; Downward J
    Cell Rep; 2018 Dec; 25(13):3545-3553.e2. PubMed ID: 30590030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.